Company

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer
Clinical trial approval / initiationDanatlas Pharmaceuticals

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals announced that the first subject has been enrolled and dosed in the Phase II clinical study of DAT‑2645, the company's independently developed Class 1 innovative drug, at the…

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

Ribo Life Science Opens Automated Intelligent Drug Screening Center – A Key Leap in AI‑Powered siRNA Drug Discovery

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerCARsgen Therapeutics

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

CRO / CMO / CDMOHKG: 2269

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
NYSE: TAKProduct approvals

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Auto-immuneHengrui Pharmaceuticals

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Show More